In particular, the overexpression of cyclin D1 (the binding partner of CDK4/6) and the loss of function of p16INK4a (endogenous CDK4/6 inhibitor) lead to abnormal function of CDK4/6, thus compromising the G1/S cell cycle checkpoint in cancer [101]. This evidence concerns the gene CDK4 and cancer.